Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All
Research at a glance
Top areas of exploration
- alpha 1-Antitrypsin Deficiency , 9 publications
- Pulmonary Disease, Chronic Obstructive , 8 publications
- alpha 1-Antitrypsin , 7 publications
- Cystic Fibrosis , 3 publications
Research activity
Active clinical trials
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in…
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All
My publications
Filter publications
44 publications
2023
Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function
Respiratory Medicine
2022
Cigarette smoke exposed airway epithelial cell-derived EVs promote pro-inflammatory macrophage activation in alpha-1 antitrypsin deficiency.
Respiratory research
•2022
Correlation of alpha-1 antitrypsin levels and exosome associated neutrophil elastase endothelial injury in subjects with SARS-CoV2 infection.
PloS one
•2022
Evaluation of Clinical Predictors for Major Outcomes in Patients Hospitalized With COVID-19: The Potential Role of the Rothman Index.
Cureus
•2022
Labelling Alpha-1 antitrypsin deficiency in the medical record - A call to action.
Respiratory medicine
•